Home / Pharmaceutical / The Pharmaceutical Market: Namibia

The Pharmaceutical Market: Namibia

Published: Jan 2015 | No Of Pages: 51 | Published By: Espicom

Product Synopsis

OVERVIEW OF THE PHARMACEUTICAL MARKET IN NAMIBIA
 
Namibia has many of the qualities exhibited by frontier pharmaceutical markets: very low percapita spending on medicines, limited access to healthcare facilities, a high prevalence of communicable diseases and constrained ability to pay for advanced therapeutics. Nevertheless, due to low growth rates in developed states, multinational drugmakers are increasingly displaying interest, albeit tentatively, in Namibia. 
 
Headline Expenditure Forecasts
  • Pharmaceuticals:NAD1.98bn (US$273mn) in 2011 to NAD2.19bn (US$268mn) in 2012; +11.0% in local currency and -1.7% in US dollar terms. Forecast slightly down in local currency termsand US dollar termsdue to macroeconomic factorsand Namibian dollar weakness, respectively.
  • Healthcare:NAD5.53bn (US$761mn) in 2011 to NAD5.94bn (US$725mn) in 2012; +7.4% in local currency and -4.8% in US dollar terms. Forecast slightly down in local currency termsand US dollar termsdue to macroeconomic factorsand Namibian dollar weakness, respectively.
  • Medical Devices: NAD0.62bn (US$85mn) in 2011 to NAD0.69bn (US$84mn) in 2012; +11.0% in local currency terms and -1.7% in US dollar terms. Forecast slightly down in local currency termsand US dollar termsdue to macroeconomic factorsand Namibian dollar weakness, respectively.
Risk/RewardRatings
 
Within the Middle East and Africa region, Namibia represents a moderately attractive proposition to foreign drugmakers, scoring 44.8 out of 100 in BMI's proprietary rankings system. This is just above the regional average of 44.2. Although the market is small in absolute terms, there is relative economic and political stability, and the government is increasing its commitment to the provision of healthcare.
 
Competitive Landscape
 
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.
BMI Industry View7
SWOT9
Political10
Economic11
Business Environment13
Industry Forecast14
Pharmaceutical Market Forecast14
 
Table: Pharmaceutical Sales, Historical Data And Forecasts (Namibia 2010-2018)15
 
Healthcare Market Forecast15
 
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2010-2018)17
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2010-2018)17
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Namibia 2010-2018)17
 
Macroeconomic Forecasts18
Industry Risk Reward Ratings23
Middle East & Africa23
Namibia Risk/Reward Ratings31
Rewards31
Risks31
Market Overview33
Industry Trends And Developments34
Healthcare Sector Developments34
Epidemiology37
Regulatory Development39
Medicine Procurement40
Demographic Forecast42
 
Table: Namibia's Population By Age Group, 1990-2020 ('000)43
Table: Namibia's Population By Age Group, 1990-2020 (% of total)44
Table: Namibia's Key Population Ratios, 1990-202045
Table: Namibia's Rural And Urban Population, 1990-202045
 
Glossary46
Methodology48
Pharmaceutical Expenditure Forecast Model48
Healthcare Expenditure Forecast Model48
Notes On Methodology49
Risk/Reward Ratings Methodology50
Ratings Overview51
 
Table: Pharmaceutical Risk/Reward Ratings Indicators51
 
Indicator Weightings52
Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +